Vimarsana
Biggest News Aggregation in the World

Page 11 - Medication Guide News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Medication Guide. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Medication Guide Today - Breaking & Trending Today

FDA Approves Expanded Indication for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) for the First-Line Treatment of Adult Patients With Locally Advanced or Metastatic Urothelial Cancer - Vimarsana News

FDA Approves Expanded Indication for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) for the First-Line Treatment of Adult Patients With Locally Advanced or Metastatic Urothelial Cancer

RAHWAY, N.J.--(BUSINESS WIRE)--Dec 15, 2023--

SCOTUS Agrees to Hear Case Will Review Fifth Circuit's Decisions on Mifepristone - Vimarsana News

SCOTUS Agrees to Hear Case Will Review Fifth Circuit's Decisions on Mifepristone

/PRNewswire/ -- We at Danco are gratified that the Supreme Court has granted Danco's and the United States' requests to review the Fifth Circuit's August...

Long-term ALPHA Phase III trial data showed danicopan as add-on to ULTOMIRIS® or SOLIRIS® sustained clinical improvements in subset of patients with PNH experiencing clinically significant extravascular hemolysis - Vimarsana News

Long-term ALPHA Phase III trial data showed danicopan as add-on to ULTOMIRIS® or SOLIRIS® sustained clinical improvements in subset of patients with PNH experiencing clinically significant extravascular hemolysis

Read trending news, stories and press releases from PMN Wire News about Canadian and international businesses.

Merck and Moderna Initiate INTerpath-002, a Phase 3 Study Evaluating V940 (mRNA-4157) in Combination with KEYTRUDA® (pembrolizumab) for Adjuvant Treatment of Patients with Certain Types of Resected Non-Small Cell Lung Cancer - Vimarsana News

Merck and Moderna Initiate INTerpath-002, a Phase 3 Study Evaluating V940 (mRNA-4157) in Combination with KEYTRUDA® (pembrolizumab) for Adjuvant Treatment of Patients with Certain Types of Resected Non-Small Cell Lung Cancer

RAHWAY, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dec 11, 2023--

New Pivotal Data for Bispecific Antibody Epcoritamab (DuoBody® CD3xCD20) Demonstrates High Overall a - Vimarsana News

New Pivotal Data for Bispecific Antibody Epcoritamab (DuoBody® CD3xCD20) Demonstrates High Overall a

Data from the pivotal phase 1/2 EPCORE™ NHL-1 study showed 82 percent overall response rate (ORR), 63 percent complete response (CR) and 67 percent minimal residual disease (MRD) negativity in patients with relapsed/refractory (R/R) follicular lymphoma (FL) treated with subcutaneous epcoritamabResults presented at t...